None

[Enanta] files for IPO

Infectious disease-focused [Enanta Pharmaceuticals Inc.] has filed for its initial public offering. The company is developing hepatitis C virus inhibitors that are designed for use in combination th...

Though Hepatitis C Patients Report Having Equal Influence with Their Treating Physicians Regarding the Management and Treatment of Their Disease, Very Few Have Ever Requested Specific Products for Treatment

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that, overall, hepatitis C (HCV) patients report...

The cyclophilin inhibitor alisporivir prevents hepatitis C virus- mediated mitochondrial dysfunction.

Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. In vitro and in vivo studies have shown that alisp...

Prospects for Interferon-Free Treatment of Hepatitis C.

Present interferon-based therapy for chronic hepatitis C (CHC) is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct acting antiviral drugs (DAAs) which inhi...